RxDoctor Payments Data

Laura Way

Psychiatric/Mental Health · Valdosta, GANPI 1366131401

Payments from drug & device makers

$3,640in general payments, 2019–2025

Across 180 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$516
  • Otsuka America Pharmaceutical, Inc.$426
  • Almatica Pharma LLC$364
  • Vanda Pharmaceuticals Inc.$359
  • Lundbeck LLC$351
  • Axsome Therapeutics, Inc.$299
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,627100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,640 in reported general payments places this provider in the 90th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$1,404
Medicare patients
15
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole27$40,901
AuvelityDextromethorphan Hbr/Bupropion13$16,810
Lurasidone Hcl25$12,140
Aripiprazole86$3,171
Quetiapine Fumarate166$1,842
Fluoxetine Hcl102$1,611
Buspirone Hcl106$1,153
Duloxetine Hcl73$1,127
Trazodone Hcl181$1,044
Oxcarbazepine20$819
Risperidone57$759
Olanzapine38$747
Sertraline Hcl120$706
Escitalopram Oxalate108$705
Doxepin Hcl28$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$426$40,90127 claims
Axsome Therapeutics, Inc.Auvelity$299$16,81013 claims
Almatica Pharma LLCSertraline Hcl$364$706120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →